No difference in myocardial iron concentration and serum ferritin with deferasirox and deferiprone in pediatric patients with hemoglobinopathies: A systematic review and meta-analysis
HematologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine
- Publicado em
- 22 jul 2022
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
No difference in myocardial iron concentration and serum ferritin with deferasirox and deferiprone in pediatric patients with hemoglobinopathies: A systematic review and meta-analysis
Arisha Saleem, Eisha Waqar, Syed Hasan Shuja, Unaiza Naeem, Abdul Moeed, Heena Rais, Jawad Ahmed
Descritores MeSH
- Hemoglobinopathies
- beta-Thalassemia
- Iron Overload
- Child
- Ferritins
- Deferiprone
- Iron
- Iron Chelating Agents
- Pyridones
- Triazoles
Veja também
Estudos relacionados
- Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia
- Oxidative stress markers and tissue iron overload after 12-months vitamin E supplementation for children with transfusion-dependent β-thalassemia on different iron chelators: A randomized placebo-controlled trial
- The impact of chelation compliance in health outcome and health related quality of life in thalassaemia patients: a systematic review
- Efficacy and Tolerability of Twice-Daily Dosing Schedule of Deferasirox in Transfusion-Dependent Paediatric Beta-Thalassaemia Patients: A Randomized Controlled Study